The anti-RSV and anti-HSV-1 activities of TA were determined by the titer reduction assay as previously described [57]. Briefly, Hep2 (to RSV) and Vero cell monolayers (to HSV-1) were co-incubated with a series of virus concentrations from 10–3 to 10–13. The cytopathogenic effect (CPE) was observed and half of tissue culture infective dose (TCID50) was calculated according to Reed & Muench formula [58].
The half toxicity (TC50) and non-cytotoxic concentration (TC0) of TA against Hep2 and Vero cells were determined using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay as previous [59].
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.
Tips for asking effective questions
+ Description
Write a detailed description. Include all information that will help others answer your question including experimental processes, conditions, and relevant images.